Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease. In recent years, interest has focused on tumors ...

Triple-negative breast cancers comprise a heterogeneous group of tumors with varying prognosis, but the majority are of high histological grade and have a poor prognosis. Although there is considerable overlap between ...